Exhibit 107

Calculation of Filing Fee Tables

Form F-3

(Form Type)

Altamira Therapeutics Ltd.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered (1)

Proposed Maximum Offering Price Per Unit (2)

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Equity

Common Shares, par value CHF 0.01 per share (3)

Other

833,334

$

0.34

$

283,333.56

0.0000927

$

26.27

–

–

–

–

Fees Previously Paid

–

–

–

–

–

–

–

–

–

–

–

–

Carry Forward Securities

Carry Forward Securities

–

–

–

–

–

–

–

–

–

–

–

–

Total Offering Amounts

$

283,333.56

$

26.27

Total Fees Previously Paid

–

Total Fee Offsets

–

Net Fee Due

$

26.27

(1)	Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminable number of additional securities that may become issuable pursuant to terms designed to prevent dilution resulting from share splits, share dividends or similar events.
(2)	Estimated in accordance with Rule 457(c) under the Securities Act solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the registrant’s common shares, as reported on the Nasdaq Capital Market on September 19, 2022, a date within five business days prior to the initial filing of this registration statement on September 23, 2022.
(3)	Consists of 833,334 common shares that may be acquired upon the exercise of the Warrants issued in connection with the Loan Agreement, dated September 9, 2022, by and between the Altamira Therapeutics Ltd., FiveT Investment Management Ltd., Dominik Lysek and Thomas Meyer.